Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial

By on    Pharma Industry News  

Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial

Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s disease (SjD) with its drug, nipocalimab. In a recent Phase 2 DAHLIAS study, patients treated with nipocalimab exhibited a statistically significant improvement in their ClinESSDAI score compared to placebo at 24 weeks (P=0.002), marking a major advancement […]

Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

By on    Pharma Industry News  

Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech company based in Cambridge, Massachusetts, which is focused on developing drugs for the treatment of rare immune-mediated diseases. As per the terms of the all-cash transaction, shareholders of Momenta Pharmaceuticals […]